Baseline risk markers and visit-to-visit variability in relation to kidney outcomes – A post-hoc analysis of the PERL study

Published:October 16, 2022DOI:



      Baseline risk variables and visit-to-visit variability (VV) of systolic blood pressure (SBP), HbA1c, serum creatinine, and uric acid (UA) are potential risk markers of kidney function decline in type 1 diabetes.


      Post-hoc analysis of a double-blind randomized placebo-controlled clinical trial investigating allopurinol’s effect on iohexol-derived glomerular filtration rate (iGFR) in type 1 diabetes with elevated UA. Primary outcome was iGFR change over three years. Linear regression with backwards selection of baseline clinical variables was performed to identify an optimized model forecasting iGFR change. Furthermore, VVs of SBP, HbA1c, serum creatinine, and UA were calculated using measurements from the run-in period; thereafter assessed by linear regression, with iGFR change as the dependent variable.


      404 participants were included in the primary analyses. In the optimized baseline variable model, higher HbA1c, SBP, iGFR, albuminuria, and heart rate, and mineralocorticoid receptor antagonist prescription were associated with greater iGFR decline. Higher VV of SBP was associated with greater iGFR decline (adjusted β (ml/min/1.73 m2/50 % increase): −0.79, p = 0.01).


      We identified several risk markers for faster iGFR decline in a high-risk population with type 1 diabetes. While further research is needed, our results indicate possible new and clinically feasible measures to risk stratify for DKD in type 1 diabetes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • de Boer I.H.
        Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.
        Diabetes Care. 2014; 37: 24-30
        • Saran R.
        • Robinson B.
        • Abbott K.C.
        • Agodoa L.Y.C.
        • Albertus P.
        • Ayanian J.
        • et al.
        US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2017; 69: A7-A8
        • Harjutsalo V.
        • Thomas M.C.
        • Forsblom C.
        • Groop P.-H.
        Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
        Diabetes, obesity & metabolism. 2018; 20: 2759-2767
        • Afkarian M.
        • Sachs M.C.
        • Kestenbaum B.
        • Hirsch I.B.
        • Tuttle K.R.
        • Himmelfarb J.
        • et al.
        Kidney disease and increased mortality risk in type 2 diabetes.
        J Am Soc Nephrol. 2013; 24: 302-308
        • Levin A.
        • Stevens P.E.
        Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward.
        Kidney Int. 2014; 85: 49-61
        • Porrini E.
        • Ruggenenti P.
        • Mogensen C.E.
        • Barlovic D.P.
        • Praga M.
        • Cruzado J.M.
        • et al.
        Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.
        Lancet Diabetes Endocrinol. 2015; 3: 382-391
        • Gorst C.
        • Kwok C.S.
        • Aslam S.
        • Buchan I.
        • Kontopantelis E.
        • Myint P.K.
        • et al.
        Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis.
        Diabetes Care. 2015; 38: 2354-2369
        • Yu Z.B.
        • Wang J.B.
        • Li D.
        • Chen X.Y.
        • Lin H.B.
        • Chen K.
        Prognostic value of visit-to-visit systolic blood pressure variability related to diabetic kidney disease among patients with type 2 diabetes.
        J Hypertens. 2019; 37: 1411-1418
        • Rotbain Curovic V.
        • Theilade S.
        • Winther S.A.
        • Tofte N.
        • Tarnow L.
        • Jorsal A.
        • et al.
        Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes.
        Diabetic Med: J Br Diabetic Association. 2021; 38: e14459
        • Doria A.
        • Galecki A.T.
        • Spino C.
        • Pop-Busui R.
        • Cherney D.Z.
        • Lingvay I.
        • et al.
        Serum urate lowering with allopurinol and kidney function in type 1 diabetes.
        N Engl J Med. 2020; 382: 2493-2503
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • Zhang Y.(.
        • Castro A.F.
        • Feldman H.I.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604
        • Gaspari F.
        • Perico N.
        • Matalone M.
        • Signorini O.
        • Azzollini N.
        • Mister M.
        • et al.
        Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.
        J Am Soc Nephrol. 1998; 9: 310-313
        • Pilemann-Lyberg S.
        • Hansen T.W.
        • Tofte N.
        • Winther S.A.
        • Theilade S.
        • Ahluwalia T.S.
        • et al.
        Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes.
        Diabetes care. 2019; 42: 1088-1094
        • Mauer M.
        • Doria A.
        Uric acid and diabetic nephropathy risk.
        Contrib Nephrol. 2018; 192: 103-109
        • Krass I.
        • Schieback P.
        • Dhippayom T.
        Adherence to diabetes medication: a systematic review.
        Diabetic Med: J Br Diabetic Association. 2015; 32: 725-737
        • Parati G.
        • Pomidossi G.
        • Albini F.
        • Malaspina D.
        • Mancia G.
        Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.
        J Hypertens. 1987; 5: 93-98
        • Kilpatrick E.S.
        • Rigby A.S.
        • Atkin S.L.
        The role of blood pressure variability in the development of nephropathy in type 1 diabetes.
        Diabetes care. 2010; 33: 2442-2447
        • Cardoso C.R.L.
        • Leite N.C.
        • Moram C.B.M.
        • Salles G.F.
        Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study.
        Cardiovasc Diabetol. 2018; 17: 33
        • McMullan C.J.
        • Lambers Heerspink H.J.
        • Parving H.-H.
        • Dwyer J.P.
        • Forman J.P.
        • de Zeeuw D.
        Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan diabetic nephropathy trial.
        Am J Kidney Dis. 2014; 64: 714-722
        • Viazzi F.
        • Bonino B.
        • Mirijello A.
        • Fioretto P.
        • Giorda C.
        • Ceriello A.
        • et al.
        Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.
        J Hypertens. 2019; 37: 805-813
        • Viazzi F.
        • Russo E.
        • Mirijello A.
        • Fioretto P.
        • Giorda C.
        • Ceriello A.
        • et al.
        Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes.
        J Hypertens. 2020; 38: 2279-2286
        • Tian X.
        • Wang A.
        • Zuo Y.
        • Chen S.
        • Zhang L.
        • Wu S.
        • et al.
        Visit-to-visit variability of serum uric acid measurements and the risk of all-cause mortality in the general population.
        Arthritis Res Ther. 2021; 23: 74
        • Mancia G.
        • Parati G.
        • Pomidossi G.
        • Casadei R.
        • Di Rienzo M.
        • Zanchetti A.
        Arterial baroreflexes and blood pressure and heart rate variabilities in humans.
        Hypertension. 1986; 8: 147-153
        • Kotsis V.
        • Stabouli S.
        • Karafillis I.
        • Papakatsika S.
        • Rizos Z.
        • Miyakis S.
        • et al.
        Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study).
        Atherosclerosis. 2011; 219: 194-199
        • Parati G.
        • Saul J.P.
        • Di Rienzo M.
        • Mancia G.
        Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation.
        Crit Appraisal Hypertension. 1995; 25: 1276-1286
        • Parati G.
        • Bilo G.
        Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability: evidence from day-by-day home blood pressure monitoring.
        Hypertension. 2012; 59: 1091-1093
        • Sega R.
        • Cesana G.
        • Bombelli M.
        • Grassi G.
        • Stella M.L.
        • Zanchetti A.
        • et al.
        Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni.
        J Hypertens. 1998; 16: 1585-1592
        • Lim H.M.
        • Chia Y.C.
        • Ching S.M.
        • Chinna K.
        Number of blood pressure measurements needed to estimate long-term visit-to-visit systolic blood pressure variability for predicting cardiovascular risk: a 10-year retrospective cohort study in a primary care clinic in Malaysia.
        BMJ Open. 2019; 9: e025322